BioWorld

Feb. 7, 2011

The Dark Side of Demand: Scaling Up Biologics

Increased demand for a drug is a welcome outcome of gaining regulatory approval and successful marketing. But scaling up production of biologics isn't easy. Read More

Money Raised Year to Date

Antitrust Probe for Alexion? History Shows No Big Deal

Obesity Drug Strike-Out May Shift Focus Back to GLP-1s

Week in Review

Word on the Street

U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010

Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010

Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...